Those treated with an SGLT2i were more than twice as likely to develop a UTI or pyelonephritis than those treated with a GLP-1 RA (RR 2.27 [95% CI 1.12, 4.55] p=0.019). This evidence concerns the gene GLP1R and bacterial urinary tract infection.